Corvus Pharmaceuticals CRVS Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $33.72M+73.9% | $19.39M+17.3% | $16.53M-32.5% | $24.47M-16.0% | ||
| $9.25M+13.3% | $8.16M+18.6% | $6.88M-15.0% | $8.1M-14.9% | ||
| $42.97M+56.0% | $27.55M+17.7% | $23.41M-28.1% | $32.57M-15.7% | ||
| -$42.97M-56.0% | -$27.55M-17.7% | -$23.41M+28.1% | -$32.57M+15.7% | ||
| -$13.33M+77.5% | -$59.1M-172% | -$21.75M+30.5% | -$31.3M— | ||
| -$15.28M+75.5% | -$62.29M-130% | -$27.03M+34.6% | -$41.31M+4.5% | ||
| -$0.50+47.4% | -$0.95-69.6% | -$0.56+37.1% | -$0.89+16.0% | ||
| -$42.87M-56.1% | -$27.46M-18.1% | -$23.26M+27.8% | -$32.2M+15.6% | ||
| -$42.97M-56.0% | -$27.55M-17.7% | -$23.41M+28.1% | -$32.57M+15.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Corvus Pharmaceuticals profitable?
- Corvus Pharmaceuticals is not currently profitable: it reported a net loss of $44.2M over the trailing twelve months.
- What is Corvus Pharmaceuticals's earnings per share?
- Corvus Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.52.
- Where does Corvus Pharmaceuticals's income statement data come from?
- Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.